Ultrasonographic Tissue Thickness After Complex Decongestive Therapy in Lower-Limb Lymphedema
Effect of Complex Decongestive Therapy on Subcutaneous Tissue Thickness in Lower-Limb Lymphedema: A Prospective Ultrasonographic Study With Contralateral Internal Control
This prospective single-center study evaluated whether 4 weeks of phase-1 complex decongestive therapy (manual lymphatic drainage, multilayer short-stretch bandaging, decongestive exercise, and skin care) changes dermal and subcutaneous tissue thickness measured by high-frequency ultrasonography in adults with unilateral International Society of Lymphology stage 1-2 lower-limb lymphedema. Measurements were made at suprapatellar and infrapatellar sites of both limbs before and after treatment; the unaffected limb served as an internal control and body weight was recorded to distinguish local tissue change from systemic weight change.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
Participants received a standardized 20-session (5 days/week, 4 weeks) intensive-phase complex decongestive therapy program delivered by an experienced physiotherapist. Ultrasonographic measurements were performed with a 10-14 MHz linear probe using a minimal-compression technique after 15 minutes of supine rest, at the same time of day, by an assessor blinded to baseline values; intra-rater reliability (intraclass correlation coefficient 0.92) was established in 10 patients. The sample size (n = 34; Cohen's d = 0.5, power 80%, alpha 0.05; 40 recruited) was calculated with G*Power. Paired comparisons (paired t-test or Wilcoxon signed-rank test), 95% confidence intervals, Cohen's d, and Pearson correlation of treatment response with age, body mass index, and disease duration were planned.
Studietype
Studietype
Registrering (Faktiske)
Registrering
Kontakter og plasseringer
Studiesteder
-
-
-
Kayseri, Tyrkia (Türkiye), 38080
- Kayseri City Training and Research Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Adults presenting to the Physical Medicine and Rehabilitation outpatient clinic of Kayseri City Hospital with unilateral lower-limb lymphedema and an indication for intensive-phase complex decongestive therapy.
Beskrivelse
Inclusion Criteria:
- Age 18 years or older
- Unilateral lower-limb lymphedema, International Society of Lymphology stage 1 or 2 (2020 consensus)
- Diagnosis supported by lymphoscintigraphy
- Indication for intensive-phase complex decongestive therapy
- No previous full course of complex decongestive therapy on the affected limb
- Written informed consent
Exclusion Criteria:
- Active cellulitis or erysipelas at the measurement sites
- Active, recurrent, or metastatic malignancy
- Decompensated heart failure or history of deep vein thrombosis
- Bilateral lymphedema
- Cognitive impairment preventing adherence to treatment
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Antall grupper / kohorter
Kohorter og intervensjoner
Gruppe / KohortGruppe / Kohort |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Lower-limb lymphedema, complex decongestive therapy
Adults with unilateral ISL stage 1-2 lower-limb lymphedema who received 4 weeks (20 sessions) of phase-1 complex decongestive therapy as standard care. Dermal and subcutaneous tissue thickness were measured by high-frequency ultrasonography at suprapatellar and infrapatellar sites of both limbs before and after treatment; the unaffected limb served as an internal control. |
Phase-1 (intensive) complex decongestive therapy delivered 5 days per week for 4 weeks (20 sessions) by an experienced physiotherapist: Vodder-technique manual lymphatic drainage (30-45 min), multilayer short-stretch compression bandaging from the toes to the proximal thigh, decongestive range-of-motion exercise performed with bandages in place, and daily skin care with a pH 5.5 moisturizer.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in subcutaneous tissue thickness of the affected limb at the suprapatellar site
Tidsramme: Baseline and end of week 4 (after 20 sessions of complex decongestive therapy)
|
Subcutaneous tissue thickness (dermis-subcutis interface to deep fascia) measured in millimeters by B-mode ultrasonography with a 10-14 MHz linear probe using a minimal-compression technique. |
Baseline and end of week 4 (after 20 sessions of complex decongestive therapy)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in subcutaneous tissue thickness of the affected limb at the infrapatellar site
Tidsramme: Baseline and end of week 4
|
Subcutaneous tissue thickness in millimeters measured by B-mode ultrasonography (10-14 MHz linear probe, minimal-compression technique). |
Baseline and end of week 4
|
|
Change in dermal thickness of the affected limb at the suprapatellar and infrapatellar sites
Tidsramme: Baseline and end of week 4
|
Dermal thickness (skin surface to dermis-subcutis interface) in millimeters measured by B-mode ultrasonography. |
Baseline and end of week 4
|
|
Change in subcutaneous tissue thickness of the unaffected (control) limb
Tidsramme: Baseline and end of week 4
|
Subcutaneous tissue thickness of the contralateral unaffected limb at the suprapatellar and infrapatellar sites, in millimeters, measured by B-mode ultrasonography; serves as an internal control. |
Baseline and end of week 4
|
|
Change in body weight
Tidsramme: Baseline and end of week 4
|
Body weight in kilograms measured on the same calibrated scale, recorded to distinguish local tissue change from systemic weight change. |
Baseline and end of week 4
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Correlation of subcutaneous thickness change with disease duration, age, and body mass index
Tidsramme: Baseline and end of week 4
|
Pearson correlation coefficients between the change in suprapatellar subcutaneous thickness of the affected limb and disease duration (months), age (years), and body mass index (kg/m2). |
Baseline and end of week 4
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Hovedetterforsker: Abdullah Goktug Yazar, MD, Kayseri City Hospital
- Studiestol: Ayse Guc, MD, Kayseri City Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- 2025-491
- 491 (Annen identifikator: Kayseri City Hospital Clinical Research Ethics Committee)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .